New findings on inhibitor development: from registries to clinical studies.
نویسندگان
چکیده
The high incidence of inhibitors against factor VIII (FVIII) concentrates in patients with haemophilia A has encouraged debate as to whether product-type plays a role. There is debate in the literature as to whether rFVIII concentrates are associated with a higher incidence of inhibitors compared to pdFVIII products. The management of haemophilia in patients with inhibitors includes on-demand/prophylaxis treatment with bypassing agents, and/or immune tolerance induction (ITI). However, these options create an economic and emotional burden on patients, their families and healthcare practitioners. Although ITI eliminates inhibitors successfully in 60-80% of cases, it is costly. Despite high costs, preliminary data from a decision analytical model have indicated that ITI is economically advantageous compared with on-demand/prophylactic treatment with bypassing agents. In patients with persistent inhibitors and those who are not candidates for ITI or have failed ITI, bleeding-related mortality and morbidity increase and quality of life decreases, compared with non-inhibitor patients. This article provides an update on the risk of inhibitor development and discusses best management approaches for patients with high-risk factors for inhibitor development.
منابع مشابه
O-32: Status of Human ART in Spain: Resultsfrom the New Registry of Catalonia
Background: FIVCAT.NET is the registry of human assisted reproductive techniques (ART) in Catalunya to which all authorised centres are obliged to declare their activities. The Background of the present study is to describe the data on effectiveness of the ART in Catalunya over the period 2001-2005 and to compare our findings with other similar registries. Materials and Methods: The data were o...
متن کاملReport of Expert Meeting on Factor Viii Products and Inhibitor Development
SUMMARY An EMEA expert meeting on FVIII products and inhibitor development was held on 28 February to 2 March 2006 to provide a forum to discuss the international standardisation and harmonisation of requirements for clinical studies on FVIII inhibitor development in haemophilia A patients. The long-term objective is to collect comparable clinical data on the immunogenicity of recombinant and p...
متن کاملTranslational Antidote Research: A Bedside to Bench Tale
Although antidote development should proceed in an orderly fashion from observation, to experimental and safety studies, to clinical trials, this sequence is not always precisely followed. The development of fomepizole as an antidote for toxic alcohol and glycol poisoning is an example of how this may not be the case. Interest in the development of fomepizole was spurred in the 1960s. Shortly t...
متن کاملInvestigation of Barium Sulfate Precipitation and Prevention Using Different Scale Inhibitors under Reservoir Conditions
In this work, scaling tendency and amount of precipitation of barium sulfate (BaSO4) were determined; the process is depending on temperature, pressure and mixing ratio of injection and formation of waters. Results showed that BaSO4 precipitation is largely dependent on mixing ratio. Temperature and pressure had no influence on BaSO4 precipitation. Different sca...
متن کاملRituximab for Treatment of Hemophilia A with High-Responder Inhibitors
Background: The development of inhibitors is a complication factor replacement therapy in hereditary factor VIII deficiency. Several management options are available for the treatment of inhibitor. Rituximab, a monoclonal antibody against CD20, reduces inhibitor level in rare bleeding disorders. The aim of this study was to evaluate the effectiveness of rituximab in lowering or eliminating the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Haemophilia : the official journal of the World Federation of Hemophilia
دوره 23 Suppl 1 شماره
صفحات -
تاریخ انتشار 2017